Ercem Atillasoy - 18 Jan 2022 Form 4 Insider Report for Allovir, Inc. (KLRS)

Role
Officer Title: Chief Regulatory and Safety Officer
Signature
/s/ Brett Hagen, as Attorney-in-Fact
Issuer symbol
KLRS
Transactions as of
18 Jan 2022
Net transactions value
$0
Form type
4
Filing time
04 Apr 2022, 16:24:34 UTC
Previous filing
25 Oct 2021
Next filing
26 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALVR Common Stock Award $0 +23,256 +23% $0.000000 123,603 18 Jan 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALVR Stock Option (Right to Buy) Award $0 +56,744 $0.000000 56,744 18 Jan 2022 Common Stock 56,744 $9.15 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
F2 25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.

Remarks:

Officer Title: Chief Regulatory and Safety Officer